Emergent BioSolutions Inc. EBS
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -163.87% | -1,401.67% | -90.00% | -74.44% | -55.40% |
| Total Depreciation and Amortization | -27.35% | 2.13% | -7.48% | -10.96% | -11.36% |
| Total Amortization of Deferred Charges | -36.00% | -33.33% | -21.74% | 18.18% | 137.31% |
| Total Other Non-Cash Items | -1,005.00% | 7,456.25% | -219.49% | 309.43% | 104.31% |
| Change in Net Operating Assets | 262.53% | -125.81% | 56.36% | 196.13% | -224.09% |
| Cash from Operations | 4,452.17% | -47.27% | -201.79% | 197.25% | -101.50% |
| Capital Expenditure | 2.94% | 27.59% | 33.33% | -129.41% | 41.38% |
| Sale of Property, Plant, and Equipment | -- | 100.00% | -- | -100.00% | -100.00% |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -352.00% | -- | -100.00% | -- |
| Cash from Investing | 235.29% | -404.07% | -104.03% | -113.64% | -103.04% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -892.75% | -- | -- | -- | 98.33% |
| Issuance of Common Stock | -50.00% | 42.86% | 300.00% | 50.00% | -97.85% |
| Repurchase of Common Stock | 96.74% | -32.39% | -2,260.00% | -3,066.67% | -2,966.67% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -332.08% | -281.25% | -2,750.00% | -22,880.00% | 91.18% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 265.14% | -117.43% | -200.85% | 21.06% | -125.53% |